

## FY23 a crucial year for AYA

AYA delivered FY22 EBITDA of **-\$16.5m** (2H22 **-\$9.9m**) and FCF of **-\$16.1m** (2H22 **-\$9.0m**), in-line with expectations after the company's 4Q22 update in Jul-22. While there was limited new information from an operational perspective in the full year accounts, we note that AYA has completed its regulatory processes review and is well progressed on an updated US approval pathway. FY23 presents as a crucial year for AYA with key catalysts including: 1) transitioning first AUS pilots to revenue; 2) early feedback from the Huntsville clinical partnership (and potential new logos in the US); 3) progress towards US market approval (510(k) resubmission and/or a De Novo application); and, 4) updates on UKCA/CE Mark approvals. We have updated forecasts noting our EBITDA estimates remain broadly unchanged and our valuation remains **\$1.44ps**.

### FY22 result highlights and outlook

Key takeaways from AYA's FY22 release include: 1) Opex increased to \$16.7m (vs \$4.2m pcp) with employee costs (\$3.4m), contractors & consultants (\$2.7m) and share-based payments (\$5.6m) all ramping up as AYA built out its global team and continued Salix development; 2) Net operating cashflow declined to **-\$9.6m** (vs **-\$1.3m** pcp) and capex (PP&E, R&D) increased to **\$6.4m** (vs **\$2.1m** pcp), taking FCF to **-\$16.1m**; and, 3) Net cash (inc term deposits) declined to **\$35.6m** (from **\$43.8m** at 1H22). We expect first revenues in FY23E (**\$0.2m** in AUS) and AYA's FCF loss to increase to **-\$23.1m** as commercialisation activities continue and opex run-rates annualise.

### Compelling technology and global team

As detailed in our recent initiation ([here](#)), AYA's Salix platform is cloud-based software that leverages proprietary AI algorithms to interpret data from CCTA scans and deliver findings rapidly at the point-of-care. Its core Salix Coronary Anatomy module is the only dedicated CAD software focusing on patient risk identification, vulnerable plaque detection and workflow optimisation (with reported vulnerable plaque biomarker specificity of 86% and balanced accuracy of 93% for stenosis >50%). Its assessment process is completed within 15 mins, offering material time / cost savings vs competing technologies and current industry practices (45+ mins for complex cases). AYA has established a high-quality, global team with the credentials to drive approval and adoption as it leverages Salix's unique value proposition (improving outcomes and productivity for patients, providers and payers).

### Valuation of \$1.44ps (DCF)

AYA's business model is capital light and highly scalable. Longer-term we see a pathway to robust unit economics, including an >80% GM and strong EBITDA/FCF generation (MSTe FY30E adj EBITDA margin 43%). **Our valuation remains unchanged at \$1.44ps** (+92% upside) based on a DCF (CoE 15.4%, TGR 3.0%), cross-checked against peer trading and transaction multiples. Key risks: regulatory approvals, market conditions, competition and access to funding.

# ARTRYA™


Artrya is an AI health-tech company, using data-driven solutions to assist cardiovascular diagnosis. Its core product Salix is a non-invasive diagnostic support solution to detect coronary artery disease. The cloud-based software draws on thousands of computed tomography coronary angiography scans to automatically detect vulnerable plaque, stenosis and other biomarkers in a patient's cardiovascular system.

[www.artrya.com](http://www.artrya.com)

Stock	AYA.AX
Price	\$0.75
Market cap	\$59m
Valuation	\$1.44ps (unchanged)

Company data	
Net cash	\$36m
Shares on issue	78.2m

Next catalysts	
Commercialisation updates	1H23
1Q23 4C report	Oct-22



Source: FactSet

**Tom Godfrey, CFA – Senior Analyst**

[tom.godfrey@mstaccess.com.au](mailto:tom.godfrey@mstaccess.com.au)

## Financials

Year end 30-Jun	Units	FY21	FY22	FY23E	FY24E	FY25E
EV/sales	x	109.5	116.8	20.0	8.1	2.5
EV/EBITDA	x	-5.7	-1.4	-1.4	-1.3	-1.6
EV/EBIT	x	-5.7	-1.4	-1.4	-1.3	-1.4
Div yield	%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF yield	%	-5.8%	-27.4%	-39.3%	-41.9%	-39.1%

Stock information	
Artrya	AYA.AX
Share Price (\$)	0.75
Valuation (\$)	1.44
Enterprise value (A\$m)	23
Market capitalisation (A\$m)	59

Income statement	Units	FY21	FY22	FY23E	FY24E	FY25E
Revenue	A\$m	0	0	1	3	9
growth y/y	%	-49%	-6%	484%	148%	227%
Gross profit	A\$m	0	0	1	2	7
Gross margin	%	100%	100%	90%	70%	75%
EBITDA	A\$m	-4	-16	-17	-18	-14
EBITDA margin	%	-1912%	-8360%	-1436%	-625%	-155%
EBIT	A\$m	-4	-17	-17	-18	-17
EBIT margin	%	-1930%	-8463%	-1454%	-638%	-180%
NPAT	A\$m	-4	-17	-17	-18	-17
NPAT margin	%	-1943%	-8708%	-1444%	-634%	-179%
Reported NPAT	A\$m	-4	-17	-17	-18	-17
Reported NPAT margin	%	-1943%	-8708%	-1444%	-634%	-179%

	1H22	2H22	1H23E	2H23E	1H24E	2H24E
	0	0	1	1	1	2
	103%	-24%	802%	341%	64%	225%
	0	0	0	1	1	1
	100%	100%	90%	90%	70%	70%
	-7	-10	-8	-8	-9	-9
	-10852%	-7243%	-1488%	-1389%	-1018%	-444%
	-7	-10	-8	-8	-9	-9
	-10887%	-7376%	-1503%	-1409%	-1035%	-455%
	-7	-11	-8	-8	-9	-9
	-10889%	-7730%	-1491%	-1402%	-1033%	-450%
	-7	-11	-8	-8	-9	-9
	-10889%	-7730%	-1491%	-1402%	-1033%	-450%

Per share data	Units	FY21	FY22	FY23E	FY24E	FY25E
Average diluted shares	m	34	66	78	131	148
EPS	cps	-12	-26	-21	-14	-11
growth y/y	%	#DIV/0!	nm	-18%	-35%	-19%
Reported EPS	cps	-12	-26	-21	-14	-11
growth y/y	%	#DIV/0!	nm	-18%	-35%	-19%
DPS	cps	0	0	0	0	0
Payout ratio	%	0%	0%	0%	0%	0%

	1H22	2H22	1H23E	2H23E	1H24E	2H24E
	55	77	78	78	113	148
	-12	-14	-10	-11	-8	-6
	nm	nm	-12%	-23%	-22%	-48%
	-12	-14	-10	-11	-8	-6
	nm	nm	-12%	-23%	-22%	-48%
	0	0	0	0	0	0
	0%	0%	0%	0%	0%	0%

Balance sheet	Units	FY21	FY22	FY23E	FY24E	FY25E
Cash	A\$m	13	36	13	35	12
Trade receivables	A\$m	1	2	2	2	3
Inventories	A\$m	0	0	0	0	0
Property, plant & equipment	A\$m	0	2	2	3	4
Right-of-use assets	A\$m	0	1	1	1	1
Goodwill	A\$m	0	0	0	0	0
Intangibles	A\$m	1	4	10	17	22
Other assets	A\$m	0	0	0	0	0
<b>Total assets</b>	<b>A\$m</b>	<b>15</b>	<b>44</b>	<b>28</b>	<b>57</b>	<b>41</b>
Trade payables	A\$m	1	1	1	1	2
Provisions	A\$m	0	0	0	0	0
Borrowings	A\$m	0	0	0	0	0
Lease liabilities	A\$m	0	1	1	1	1
Other liabilities	A\$m	0	0	0	0	0
<b>Total liabilities</b>	<b>A\$m</b>	<b>1</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>
<b>Total equity</b>	<b>A\$m</b>	<b>14</b>	<b>41</b>	<b>25</b>	<b>54</b>	<b>38</b>
Invested capital	A\$m	1	5	12	19	26
<b>Net debt</b>	<b>A\$m</b>	<b>-13</b>	<b>-36</b>	<b>-13</b>	<b>-35</b>	<b>-12</b>

Performance metrics	FY22	FY23E	FY24E	FY25E
ROE (%)	-63%	-51%	-47%	-37%
ROIC (%)	nm	-164%	-110%	-73%
Gearing (%)	0%	0%	0%	0%
ND / EBITDA (x)	nm	nm	nm	nm
EBITDA int cover (x)	nm	nm	nm	nm
EBIT int cover (x)	nm	nm	nm	nm
NWC (A\$m)	0	1	1	1
Gross OCF / EBITDA (%)	nm	nm	nm	nm
Capex / sales (%)	3239%	609%	270%	91%
EBITDA growth (%)	310%	0%	8%	-19%
EBIT growth (%)	311%	0%	9%	-8%
P/FCF (x)	-3.7	-2.5	-2.4	-2.6
P/BV (x)	1.4	2.4	1.1	1.5

Company description - AYA.AX	
<b>Artrya</b>	
Artrya is an AI health-tech company, using data-driven solutions to assist cardiovascular diagnosis. Its core product Salix is a non-invasive diagnostic support solution to detect coronary artery disease. The cloud-based software draws on thousands of computed tomography coronary angiography scans to automatically detect vulnerable plaque, stenosis and other biomarkers in a patient's cardiovascular system.	


Cash flow statement	Units	FY21	FY22	FY23E	FY24E	FY25E
EBITDA	A\$m	-4	-16	-17	-18	-14
Change in NWC	A\$m	0	0	0	0	1
Other	A\$m	2	7	0	1	-1
Gross operating cash flow	A\$m	-1	-10	-16	-17	-14
Net interest	A\$m	0	0	0	0	0
Tax paid	A\$m	0	0	0	0	0
<b>Operating cash flow</b>	<b>A\$m</b>	<b>-1</b>	<b>-10</b>	<b>-16</b>	<b>-17</b>	<b>-14</b>
Capital expenditure	A\$m	-2	-6	-7	-8	-8
Acquisitions	A\$m	0	0	0	0	0
Asset sales	A\$m	0	0	0	0	0
Other	A\$m	0	0	0	0	0
<b>Investing cash flow</b>	<b>A\$m</b>	<b>-2</b>	<b>-6</b>	<b>-7</b>	<b>-8</b>	<b>-8</b>
Net borrowings	A\$m	0	0	0	0	0
Dividends paid	A\$m	0	0	0	0	0
New shares issued / other	A\$m	14	39	0	47	0
<b>Financing cash flow</b>	<b>A\$m</b>	<b>14</b>	<b>39</b>	<b>0</b>	<b>47</b>	<b>0</b>
<b>Net change in cash</b>	<b>A\$m</b>	<b>11</b>	<b>23</b>	<b>-23</b>	<b>22</b>	<b>-23</b>
<b>Free cash flow</b>	<b>A\$m</b>	<b>-3</b>	<b>-16</b>	<b>-23</b>	<b>-25</b>	<b>-23</b>

Source: Company data, MST

## Investment Thesis

AYA's Salix SaaS solution is set to disrupt CCTA and ICA, the two gold standards of CAD detection. In our view, AYA has developed a technology platform and global team that can deliver significant installed base growth in markets that facilitate >16m procedures pa (with an initial revenue opportunity of A\$0.8-1.2b).


AYA's market opportunity is significant and benefits from structural growth as CCTA utilisation lifts...



Source: Frost & Sullivan, company data, HeartFlow, MST

AYA's core Salix Coronary Anatomy module is the only dedicated CAD software focusing on patient risk identification, vulnerable plaque detection and workflow optimisation (with reported vulnerable plaque biomarker specificity of 86% and balanced accuracy of 93% for stenosis >50%). Its assessment process is completed within 15 mins, offering material time / cost savings vs competing technologies and current industry practices (45+ mins for complex cases).


Salix offers significant accuracy & workflow efficiency gains, benefitting patients, providers and payers...



Source: Company data, MST

We forecast rapid Salix revenue growth once AYA achieves key regulatory approvals and begins to expand its installed base (\$8.3m by FY25E with a 63% 5yr CAGR thereafter). We expect the majority of this growth to come from the US market, underpinned by value-based care contracts with key integrated delivery networks and accountable care organisations.

We forecast \$97m of global Salix revenue by FY30E (69% US) representing <4% penetration



Source: Company data, MST

## Key risks

Key risks to our investment thesis for AYA include:

- **Market conditions** – To meet our revenue forecasts, AYA’s sales and marketing activities must generate new research agreement/contract wins. If the investment environment for hospitals/imaging groups is impacted by macro factors (economic activity, COVID-19, etc) then this could negatively impact AYA’s ability to drive software revenue growth (offset by the fact that capex requirements are minimal);
- **Competition** – AYA operates in a competitive industry. Competitors could impact AYA’s market share gains via marketing campaigns, product research and development, strategic alliances with industry bodies, favourable distribution partnerships, price discounting or acquisitions. We also note that existing or new competitors may develop new products (or improve existing products), which may improve their competitive positioning relative to AYA;
- **Product development and approval** – AYA’s product candidates are at a relatively early clinical stage and further clinical study using varied patient populations is necessary. No guarantee can be provided that AYA’s clinical work will result in an approved product in key jurisdictions;
- **Customers** – The success of AYA’s business relies on its ability to attract new customers. AYA generates revenue through customers utilising Salix and being charged via Pay-Go or a subscription fee. There is a risk that future customers may reduce or cease usage of AYA’s services or that they may not increase their usage, which would result in a reduction, or limited growth, in AYA revenues;
- **Future profitability** – AYA is still in the early sales and commercialisation stage for Salix. To date, it has funded its operations principally through issuing securities, seeking research and development tax refunds and by applying for grants. AYA is not yet profitable and has historically incurred losses. There is no guarantee that AYA will be able to grow its product sales in any jurisdiction. Regulatory approvals and adoption of AYA’s products remain crucial for long-term revenue generation and future profitability;
- **Future funding requirements** – In the future, AYA may need to raise capital through public or private markets to meet its business objectives. There is a risk that such funding is not available on favourable terms, or at all, which could negatively impact AYA’s business / growth ambitions;
- **Pricing** – AYA’s customers may try to renegotiate contract terms for more favourable pricing, which would result in a direct reduction in revenue generated. To stay competitive AYA may need to adjust pricing models in response to customer behaviour, including changes in demand for different products, contract terms or changes in customer preferences in terms of how they choose to interact with AYA;
- **Key personnel** – The recruitment and retention of key personnel including senior management is critical to AYA’s success. Any unexpected departures would present increased strategic and operational execution risks and would likely result in negative share price action for AYA; and
- **Foreign exchange** – Revenue generated and expenditure incurred overseas will be subject to foreign exchange risk. AYA’s payment obligations under some of its material contracts are in foreign currencies. AYA does not plan at this stage to hedge its foreign currency payments;
- **Reimbursement** – In both domestic and foreign markets, sales of AYA’s products are likely to depend in part upon the availability and amounts of reimbursement from third-party healthcare payer organisations, including government agencies, private healthcare insurers and other payers;
- **Technology** – AYA and its customers are dependent on the performance, reliability and availability of the company’s technology, third-party data centres and communications systems. There is a risk that these systems may fail or be adversely impacted by several factors; and
- **Intellectual property** – AYA’s success (to a large extent), will depend on its ability to obtain patents, as well as maintain both trade secrets and copyright protection over its proprietary software and algorithms. It will also depend on its ability to operate without infringing the proprietary rights of third parties. AYA’s patent applications are still pending. Examination of patent applications may be expensive and time-consuming, with no guarantee that lodged patent applications will result in granted patents.

## Disclaimers and Disclosures

MST Access is a registered business name of MST Financial Services Pty Ltd (ACN 617 475 180 "MST Financial") which is a limited liability company incorporated in Australia on 10 April 2017 and holds an Australian Financial Services Licence (Number: 500 557). This research is issued in Australia through MST Access which is the research division of MST Financial. The research and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by MST Access is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a financial product you should read any relevant Product Disclosure Statement or like instrument.

This report has been commissioned by Artrya and prepared and issued by Tom Godfrey, CFA of MST Access in consideration of a fee payable Artrya. MST Access receives fees from the company referred to in this document, for research services and other financial services or advice we may provide to that company.

MST Financial also provides equity capital markets ("ECM") and corporate advisory services through its capital markets division, MST Capital Markets ("MST Capital"). MST Capital provides these services to a range of companies including clients of the MST Access service. As such, MST Capital may in future provide ECM and/or corporate advisory services to the company that is the subject of this research report and, accordingly, may receive fees from the company for providing such services. MST Financial has measures in place to ensure the independence of its research division is maintained, including information barriers between its Capital Markets and Research teams. In addition, neither MST Access, nor any of its research analysts, receive any financial benefit that is based on the revenues generated by MST Capital Markets or any other division of MST Financial.

The analyst has received assistance from the company in preparing this document. The company has provided the analyst with communication with senior management and information on the company and industry. As part of due diligence, the analyst has independently and critically reviewed the assistance and information provided by the company to form the opinions expressed in the report. Diligent care has been taken by the analyst to maintain an honest and fair objectivity in writing this report and making the recommendation. Where MST Access has been commissioned to prepare content and receives fees for its preparation, please note that NO part of the fee, compensation or employee remuneration paid will either directly or indirectly impact the content provided.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently certified. Opinions contained in this report represent those of MST Access at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results and estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of liability: To the fullest extent allowed by law, MST Access shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained in this report. No guarantees or warranties regarding accuracy, completeness or fitness for purpose are provided by MST Access, and under no circumstances will any of MST Financial's officers, representatives, associates or agents be liable for any loss or

damage, whether direct, incidental or consequential, caused by reliance on or use of the content.

## General Advice Warning

MST Access Research may not be construed as personal advice or recommendation. MST encourages investors to seek independent financial advice regarding the suitability of investments for their individual circumstances and recommends that investments be independently evaluated. Investments involve risks and the value of any investment or income may go down as well as up. Investors may not get back the full amount invested. Past performance is not indicative of future performance. Estimates of future performance are based on assumptions that may not be realised. If provided, and unless otherwise stated, the closing price provided is that of the primary exchange for the issuer's securities or investments. The information contained within MST Access Research is published solely for information purposes and is not a solicitation or offer to buy or sell any financial instrument or participate in any trading or investment strategy. Analysis contained within MST Access Research publications is based upon publicly available information and may include numerous assumptions. Investors should be aware that different assumptions can and do result in materially different results.

MST Access Research is distributed only as may be permitted by law. It is not intended for distribution or use by any person or entity located in a jurisdiction where distribution, publication, availability or use would be prohibited. MST makes no claim that MST Access Research content may be lawfully viewed or accessed outside of Australia. Access to MST Access Research content may not be legal for certain persons and in certain jurisdictions. If you access this service or content from outside of Australia, you are responsible for compliance with the laws of your jurisdiction and/or the jurisdiction of the third party receiving such content. MST Access Research is provided to our clients through our proprietary research portal and distributed electronically by MST to its MST Access clients. Some MST Access Research products may also be made available to its clients via third party vendors or distributed through alternative electronic means as a convenience. Such alternative distribution methods are at MST's discretion.

## Access and Use

Any access to or use of MST Access Research is subject to the [Terms and Conditions](#) of MST Access Research. By accessing or using MST Access Research you hereby agree to be bound by our Terms and Conditions and hereby consent to MST collecting and using your personal data (including cookies) in accordance with our [Privacy Policy](#) (<https://mstfinancial.com.au/privacy-policy/>), including for the purpose of a) setting your preferences and b) collecting readership data so we may deliver an improved and personalised service to you. If you do not agree to our Terms and Conditions and/or if you do not wish to consent to MST's use of your personal data, please do not access this service.

Copyright of the information contained within MST Access Research (including trademarks and service marks) are the property of their respective owners. MST Access Research, video interviews and other materials, or any portion thereof, may not be reprinted, reproduced, sold or redistributed without the prior written consent of MST.

Level 13, 14 Martin Place, Sydney, NSW 2000  
Main +61 2 8999 9988  
[www.mstfinancial.com.au](http://www.mstfinancial.com.au)